In the News

Mark Mansour Addresses District Court Ruling on FDA Drug Designations in Law360

April 30, 2021

Mark Mansour, Washington, D.C.-based Member in Dykema’s Health Care practice group, was quoted in the Law360 article, “FDA Faces Fresh Drug-Device Headaches After DC Circ. Loss.”

In the article, Mansour commented on the recent Washington, D.C., District Court ruling regarding the FDA’s usual practice of designating a product as a drug when it falls into the definition of both a drug and a medical device. Mansour said he believes it will make it more difficult for the FDA to call a product a drug whenever there is a question.

To read the entire article, click here.